Steven Masson

Has grant

Honorary Clinical Senior Lecturer

Newcastle University

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Steven Masson is an Honorary Clinical Senior Lecturer at Newcastle University in the UK. His research primarily focuses on liver disease, particularly in relation to alcohol-related hepatitis, advanced liver fibrosis, and the role of transplantation. Recent publications include investigations into the efficacy of IL-1 signal inhibition and the identification of transplant recipients through novel biomarker strategies.

Recent Grants

Grant: Close

An adaptive-design randomised placebo-controlled trial of baclofen in the treatment of alcohol use disorder in patients with liver cirrhosis (BASIS)

Open Date: 2021-10-01

Close Date: 2025-09-30

Grant: Close

Genetic risk factors for alcoholic cirrhosis - genome-wide case-control study

Open Date: 2018-09-25

Close Date: 2022-06-30

Grant: Close

Prospective randomised marker-based trial to assess the clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation.

Open Date: 2015-04-01

Close Date: 2021-12-31

Grant: Close

Genetic risk factors for alcoholic cirrhosis - genome-wide case-control study

Open Date: 2011-09-20

Close Date: 2020-06-30

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (16)

Richard Parker

UNITED KINGDOM

Steven Masson

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Plasma exchange does not improve overall survival in patients with acute liver failure in a real-world cohort

IL-1 Signal Inhibition in Alcohol-Related Hepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial of Canakinumab

UK needs national strategy to tackle alcohol related harms

Women and People From Deprived Areas Are Less Likely to be Assessed for Liver Transplantation for Alcohol-related Liver Disease: Results From a National Study of Transplant Assessments

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply

Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2‐F3 fibrosis. Authors' reply

How effective are experienced hepatologists at staging fibrosis using non‐invasive fibrosis tests in patients with metabolic dysfunction‐associated steatotic liver disease?

Randomized trial investigating the utility of a liver tissue transcriptional biomarker in identifying adult liver transplant recipients not requiring maintenance immunosuppression

A polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry

Improving survival in alcohol-related hepatitis: what's new?

British Society of Gastroenterology Best Practice Guidance: outpatient management of cirrhosis – part 1: compensated cirrhosis

British Society of Gastroenterology Best Practice Guidance: outpatient management of cirrhosis – part 2: decompensated cirrhosis

British Society of Gastroenterology Best Practice Guidance: outpatient management of cirrhosis – part 3: special circumstances

Where does genetic testing fit in the diagnostic pathway of patients with cryptogenic cirrhosis?

Extra‐hepatic morbidity and mortality in alcohol‐related liver disease: Systematic review and meta‐analysis

In severe alcohol‐related hepatitis, acute kidney injury is prevalent, associated with mortality independent of liver disease severity, and can be predicted using IL‐8 and micro‐RNAs

Deaths from alcohol-related liver disease in the UK: an escalating tragedy.

All-cause and liver-related mortality risk factors in excessive drinkers: Analysis of data from the UK biobank.

Outcomes After Liver Transplantation With Incidental Cholangiocarcinoma.

Restoring cellular magnesium balance through Cyclin M4 protects against acetaminophen-induced liver damage.

Collaborators (16)

Richard Parker

Francesca Fiorentino

Nick Murphy

Michael Heneghan

james ferguson

cesar martin

Maja Thiele

Quentin M. Anstee

Ewan Forrest

William Bernal

Robert Hunter

Neil Halliday

Tiebing Liang

Ashwin D. Dhanda

Ann Daly

Alberto Sanchez-Fueyo

Make your next move.